Home
HomeSite Index Maps & Directions Contact Us
Find a Doctor
Consumer Health Information
About University Health Systems
Patient and Visitor Information
Jobs
Graduate Medical Education
Our Hospitals
Pitt County Memorial Hospital
Bertie Memorial Hospital
Chowan Hospital
Heritage Hospital
The Outer Banks Hospital
Roanoke-Chowan Hospital
Cardiovascular Center
Children's Hospital
Leo Jenkins Cancer Center
Regional Rehabilitation Center
Trauma and Critical Care
Women's Services
Surgical Services
Outpatient Services
ViQuest
All Services
Quick Links








Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Cancer Drug Gleevec Linked to Muscle Damage


French researchers say the problem can probably strike small percentage of patients

WEDNESDAY, June 18 (HealthDay News) -- French doctors have reported a possible new side effect associated with the cancer drug Gleevec (imatinib), widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.

In a letter published in the June 19 issue of the New England Journal of Medicine, the doctors describe the case of a 25-year-old woman who developed severe rhabdomyolysis while taking imatinib.

Rhabdomyolysis is the breakdown of muscle fibers resulting in the release of muscle fiber contents (myoglobin) into the bloodstream. The condition can cause kidney damage.

The woman was taking imatinib (daily dose of 400 mg) in a clinical trial for the treatment of aggressive fibromatosis (desmoid tumors) that couldn't be treated with surgery. Shortly after the start of drug treatment, the woman experienced symptoms of rhabdomyolysis.

After she stopped taking imatinib, her symptoms ceased. She then agreed to take the drug again while under medical surveillance. Twenty-four hours after she received the first daily dose of 100 mg, she suffered severe symptoms. The drug treatment was halted, and her symptoms disappeared in three days.

The woman's desmoid tumors were treated with radiotherapy, and she has not experienced any recurrence of rhabdomyolysis symptoms.

"We considered our patient's rhabdomyolysis to be induced by imatinib because of the temporal relationship (the rhabdomyolysis occurred within a few days after the initiation of imatinib therapy), the recurrence of rhabdomyolysis with the reintroduction of the drug, and normalization of the creatine kinase level after discontinuation of the drug. Although there is extensive clinical experience with the safe use of imatinib, this observation suggests that the drug may cause severe rhabdomyolysis in a small proportion of patients," the doctors wrote.

Earlier this year, a case report by Greek doctors suggested that imatinib may disrupt ovarian function and impair fertility. It was published as a letter in the New England Journal of Medicine.

More information

The MedlinePlus Medical Encyclopedia has more about rhabdomyolysis.

SOURCE: New England Journal of Medicine, news release, June 18, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision
Disclaimer Information Calendar of Events Privacy Practices Copyright 2005